Decoding biology just got a significant boost as Recursion recently announced raising an impressive $200,000,000 in funding. The clinical-stage TechBio company is on a mission to revolutionize drug discovery by seamlessly integrating cutting-edge technologies in biology, chemistry, automation, data science, and engineering. By industrializing the drug discovery process, Recursion aims to decode complex biology through innovative approaches. With a vision to radically improve lives through biology, the company is committed to leveraging diverse expertise, backgrounds, and perspectives to drive its pioneering research forward. Based in Salt Lake City, Recursion is at the forefront of decoding biology to unlock new possibilities in the field of biopharmaceuticals.





